1. Home
  2. HEQ vs LPTX Comparison

HEQ vs LPTX Comparison

Compare HEQ & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HEQ
  • LPTX
  • Stock Information
  • Founded
  • HEQ 2011
  • LPTX 2011
  • Country
  • HEQ United States
  • LPTX United States
  • Employees
  • HEQ N/A
  • LPTX N/A
  • Industry
  • HEQ Investment Managers
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • HEQ Finance
  • LPTX Health Care
  • Exchange
  • HEQ Nasdaq
  • LPTX Nasdaq
  • Market Cap
  • HEQ 127.0M
  • LPTX 119.6M
  • IPO Year
  • HEQ N/A
  • LPTX N/A
  • Fundamental
  • Price
  • HEQ $10.50
  • LPTX $0.28
  • Analyst Decision
  • HEQ
  • LPTX Buy
  • Analyst Count
  • HEQ 0
  • LPTX 2
  • Target Price
  • HEQ N/A
  • LPTX $8.00
  • AVG Volume (30 Days)
  • HEQ 43.1K
  • LPTX 3.0M
  • Earning Date
  • HEQ 01-01-0001
  • LPTX 08-11-2025
  • Dividend Yield
  • HEQ 9.78%
  • LPTX N/A
  • EPS Growth
  • HEQ N/A
  • LPTX N/A
  • EPS
  • HEQ N/A
  • LPTX N/A
  • Revenue
  • HEQ N/A
  • LPTX N/A
  • Revenue This Year
  • HEQ N/A
  • LPTX N/A
  • Revenue Next Year
  • HEQ N/A
  • LPTX N/A
  • P/E Ratio
  • HEQ N/A
  • LPTX N/A
  • Revenue Growth
  • HEQ N/A
  • LPTX N/A
  • 52 Week Low
  • HEQ $9.08
  • LPTX $0.22
  • 52 Week High
  • HEQ $11.84
  • LPTX $4.79
  • Technical
  • Relative Strength Index (RSI)
  • HEQ 54.54
  • LPTX 29.63
  • Support Level
  • HEQ $10.37
  • LPTX $0.27
  • Resistance Level
  • HEQ $10.56
  • LPTX $0.44
  • Average True Range (ATR)
  • HEQ 0.08
  • LPTX 0.04
  • MACD
  • HEQ -0.02
  • LPTX -0.01
  • Stochastic Oscillator
  • HEQ 50.00
  • LPTX 3.45

About HEQ John Hancock Hedged Equity & Income Fund of Beneficial Interest

John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return with a focus on current income and gains and also consisting of long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

Share on Social Networks: